PeptideTreatments
Reviewed by Peptide Treatments Medical Advisory Board

Danuglipron: Research & Evidence

Emerging Evidence

Published research, clinical trial data, and evidence grading for Danuglipron across studied indications.

Back to Danuglipron overview

Research Summary

Danuglipron has completed Phase 2b testing in obesity (NCT04707313, N=610) showing 8-13% placebo-adjusted weight loss at 32 weeks, and Phase 2 in Type 2 diabetes (NCT04034303, N=411) demonstrating glycemic control. The initial twice-daily formulation had high GI adverse event rates, prompting development of a once-daily formulation that met PK objectives in dose-optimization studies (NCT06567327, NCT06568731). No observed liver enzyme elevations across 1,400+ participants. Phase 3 trials with the optimized once-daily formulation are anticipated. Not FDA-approved as of March 2026.

Evidence by Indication (3 indications)

Indication Tier Trials Summary
Obesity/weight loss Tier B 1 Phase 2b RCT (N=610) showed 8-13% weight loss at 32 weeks
Type 2 diabetes Tier B 1 Phase 2 RCT (N=411) demonstrated glycemic control
MASH/NAFLD Tier D 0 No trials — theoretical benefit from GLP-1 class

Graded using our evidence tier methodology.

Research Gap Score /10

Higher score = larger gap between therapeutic potential and available clinical evidence.

Citations (2 sources)

  1. 1. Phase 2b trial of danuglipron in adults with obesity Clinical Trial

    Pfizer Clinical Trial Investigators (2025), Obesity

  2. 2. Phase 2 trial of danuglipron in Type 2 diabetes Clinical Trial

    Pfizer Clinical Trial Investigators (2023), Diabetes Care